Nuvonis is a biotech company based in Vienna, Austria, providing innovative Cell Banks and technical support for vaccine development. The Nuvonis team is highly experienced in all aspects of vaccine production, both in small biotech companies up to major international pharmaceutical companies. We have identified several weak points in vaccine production that usually result in significant delays in product development, both on the side of cell substrates and in process development for production. Based on our experience, Nuvonis offers solutions that reduce development timelines, ensure optimal quality and prevent risks in your product development.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
Nuvonis is a biotech company based in Vienna, Austria, providing innovative cell banks and technical support for vaccine process development. We are highly experienced in cell line development, vaccine manufacturing, process optimization for vaccine / vector production and fast potency testing.
The fully characterized Nuvonis Vero Cells (GMP) are cultivated without animal-derived media or protease additives and are non-tumorigenic beyond the end of production passage. This Cell Bank can be licensed for viral vaccine and vector manufacturing to immediately move into GMP production of your product.
To help you fulfill the most demanding timelines in your GMP production, the Nuvonis GMP Vero cells are now also available from a USA storage facility. No complicated transatlantic shipments, get GMP-grade and ready-to-use Vero cell banks for your production needs within days. With respect to GMP storage, we work with the renowned Charles River Laboratories and use their GMP-compliant facilities located in Wayne, PA and/ or Shrewsbury, MA.
A proprietary Avian Cell Bank is growing on microcarrier or in suspension can be licensed for viral vaccine and vector manufacturing.
We are offering proprietary and efficient virus purification processes for the generation of high purity vaccine bulk drug substance with low host cell DNA and protein impurities.
'Ready to use' R&D and GMP Cell Banks for vaccine manufacturing
Nuvonis Cell Banks are state- of-the-art as they were generated under serum free and animal component free conditions and grow in medium that is commercially available. Currently, fully tested Vero Cell Banks (both GMP and R&D) and a novel avian cell line (quail) is available.
Process development for vaccine manufacturing (upstream/downstream)
The NUVONIS team is highly experienced in the development and optimization of up- and downstream vaccine production processes. We are offering a proprietary and efficient virus purification process for the generation of high purity vaccine bulk drug substance meeting regulatory requirements in terms of host cell DNA and host cell protein limits.
Influenza virus generation by reverse genetics
The NUVONIS team is highly experienced in the generation of influenza viruses by reverse genetics. Nuvonis uses a proprietary method to generate vaccine strains within days in serum-free Vero cells. The method is extremely fast, efficient, and reliable